ONYX Pharmaceuticals

Onyx field reps spared in Amgen's 300-job bloodletting
Onyx field reps spared in Amgen's 300-job bloodletting
Fierce Pharma Marketing
ONYX Pharmaceuticals
Amgen
M&A
layoffs
drug reps
Flag link:
Was Onyx worth it? Amgen's case is looking up as Kyprolis bests Velcade in head-to-head trial
Was Onyx worth it? Amgen's case is looking up as Kyprolis bests Velcade in head-to-head trial
Fierce Pharma
ONYX Pharmaceuticals
Amgen
Velcade
Kyprolis
Multiple Myeloma
Flag link:
Former Onyx CEO Returns to Biotech to Launch Boston Start Up
Former Onyx CEO Returns to Biotech to Launch Boston Start Up
TheStreet.com
Tony Coles
ONYX Pharmaceuticals
Yumanity Therapeutics
Flag link:
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Yahoo/PR Newswire
Amgen
ONYX Pharmaceuticals
Kyprolis
Multiple Myeloma
Flag link:
Bayer, Onyx Pharma Say Phase 3 Trial Of NEXAVAR Fails To Meet Primary Endpoint
Bayer, Onyx Pharma Say Phase 3 Trial Of NEXAVAR Fails To Meet Primary Endpoint
RTT News
Bayer
ONYX Pharmaceuticals
Nexavar
breast cancer
Flag link:
Will Amgen’s Acquisition of Onyx Pay off Soon?
Will Amgen’s Acquisition of Onyx Pay off Soon?
Motley Fool
M&A
Amgen
ONYX Pharmaceuticals
Kyprolis
Multiple Myeloma
Flag link:
Top 10 Pharma M&A deals of 2013
Top 10 Pharma M&A deals of 2013
Fierce Pharma
M&A
Amgen
ONYX Pharmaceuticals
Bausch & Lomb
Valeant Pharmaceuticals
Elan
Perrigo
Actavis
Warner Chilcott
Bristol-Myers Squibb
AstraZeneca
Pearl Therapeutics
Agila
Mylan
Salix
Santarus
Bayer
Algeta
Shire
ViroPharma
Flag link:
Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met
Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met
Bloomberg
Bayer
ONYX Pharmaceuticals
Nexavar
liver cancer
Flag link:
The Best Biotech CEO of 2013 is...
The Best Biotech CEO of 2013 is...
TheStreet.com
biotech
Celgene
NPS Pharmaceuticals
Bristol-Myers Squibb
ONYX Pharmaceuticals
Flag link:
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
Yahoo/PR NewsWire
Nexavar
Bayer
ONYX Pharmaceuticals
Amgen
thyroid cancer
refractory differential thyroid cancer
Flag link:
U.S. judge throws out SEC lawsuit over 'suspicious' Onyx trading
U.S. judge throws out SEC lawsuit over 'suspicious' Onyx trading
Yahoo/Reuters
ONYX Pharmaceuticals
SEC
lawsuits
Flag link:
Northwest Biotherapeutics Poses Onyx Like Potential
Northwest Biotherapeutics Poses Onyx Like Potential
Seeking Alpha
Northwest Biotherapeutics
Agenus
Celldex
ONYX Pharmaceuticals
ImmunoCellular Therapeutics
Flag link:
Karyopharm Therapeutics IPO Looks Promising
Karyopharm Therapeutics IPO Looks Promising
Seeking Alpha
Karyopharm
IPOs
Pfizer
Aveo Oncology
ONYX Pharmaceuticals
Flag link:
Top 15 Drug Launch Superstars
Top 15 Drug Launch Superstars
Fierce Pharma
drug launches
Eylea
Regeneron
Bayer
Tecfidera
Biogen Idec
Kalydeco
Vertex Pharmaceuticals
Kadcyla
Roche
Genentech
Victoza
Novo Nordisk
Gilenya
Novartis
Zytiga
JNJ
Yervoy
Bristol-Myers Squibb
Stribild
Gilead Sciences Xtandi
Medivation
Astellas
Afinitor
Amgen
Prolia
Stelara
Kyprolis
Xarelto
ONYX Pharmaceuticals
Flag link:
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Yahoo
Amgen
ONYX Pharmaceuticals
M&A
Flag link:
Amgen's 10 Billion Dollar Molecule
Amgen's 10 Billion Dollar Molecule
Seeking Alpha
Amgen
Takeda
ONYX Pharmaceuticals
Kyprolis
Flag link:
3 Signs We Could Be Entering a Biotech Bubble
3 Signs We Could Be Entering a Biotech Bubble
Motley Fool
biotech
Perrigo
Bristol-Myers Squibb
Elan
Clovis Oncology
IPOs
Stemline
Amgen
Biogen Idec
ONYX Pharmaceuticals
Flag link:
With $29B in deals so far, 2013 shaping up as big M&A year
With $29B in deals so far, 2013 shaping up as big M&A year
Fierce Pharma
M&A
Valeant Pharmaceuticals
Bausch & Lomb
ONYX Pharmaceuticals
Amgen
Flag link:
Top Biotech Stock Picks for Q4 2013: An Interview with the Senior Analyst at Oppenheimer & Company
Top Biotech Stock Picks for Q4 2013: An Interview with the Senior Analyst at Oppenheimer & Company
Yahoo/Wall St Transcript
Amgen
Celgene
ONYX Pharmaceuticals
Keryx
Pluristem Therapeutics
NPS Pharmaceuticals
Flag link:
Amgen With Onyx Pharmaceuticals: Long-Term Analysis
Amgen With Onyx Pharmaceuticals: Long-Term Analysis
Seeking Alpha
Amgen
ONYX Pharmaceuticals
M&A
Flag link:

Pages